sutrobio.com - STRO Income before deduction of interest, taxes and amortization

Graphic logo of Sutro Biopharma Inc. (STRO)

Fierce competition in the conjugate segment is forcing Sutro Biopharma, Inc. (STRO) to fight for leadership. The company's consolidated EBITDA clearly illustrates the financial dynamics, where 0.00 determines the current status of the parameter. Business resilience relies on strategic alliances with pharma behemoths, while the breakthrough potential of the XMT platform for the therapy of lymphomas and ovarian cancer confirms the high investment attractiveness of its developments.

Profit before payment of interest, taxes and amortization: Sutro Biopharma, Inc. (STRO) for 11/23/2025 - 11/10/2026

Sutro Biopharma - analytical breakdowns and key metrics (STRO)

- market value and analyst target forecast:
Market Price Sutro Biopharma, Inc|STRO - Consensus Target
- issuer market value details:
Market Value Sutro Biopharma|STRO - Enterprise Value
- book capitalization information:
Net Assets per Share Sutro Biopharma|STRO - Company Book Value|Market Cap to Net Assets Ratio sutrobio.com|STRO - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Sutro Biopharma, Inc.|STRO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Sutro Biopharma Inc.|STRO - Company Debts|Debt to Book Value Ratio Sutro Biopharma|STRO - Company Long-Term Debt|Short-Term Debt Sutro Biopharma|Critical Liquidity sutrobio.com
- company profitability and valuation multiples indicators:
STRO - Net Income|Future Net Profit Sutro Biopharma, Inc.|STRO - P/E Multiple|Future Price to Earnings Multiple sutrobio.com|STRO - PEG Multiple|Company Value to EBITDA Sutro Biopharma|STRO - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Sutro Biopharma|STRO - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth sutrobio.com|STRO - Earnings per share growth in current year|Net earnings per share change forecast for next year Sutro Biopharma, Inc.
Analysis of all company metrics:Sutro Biopharma, Inc - STRO
Mass-produced product of Sutro Biopharma

The operational success of Sutro Biopharma, Inc. (STRO) depends on the ability of R&D alliances with Big Pharma to cover antibody development costs. By analyzing current operating profit in cash terms on GURU.Markets, an investor assesses the net cash flow before depreciation and taxes, which allows for the determination of the business's real valuation foundation excluding capital expenditures and confirms the company's financial stability.

Competitors of Sutro Biopharma, Inc. (STRO)

NantKwest (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (januxrx.com)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|Operating profit before deduction of amortization xencor.com XNCR|Compass Therapeutics, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Group Inc REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (Innate Pharma S.A) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen (CGEN)|Operating profit before deduction of amortization IOBT|INKT - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|Income before deduction of interest, taxes and amortization CUE|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus - Income before deduction of interest, taxes and amortization|LVTX (LAVA Therapeutics NV) - Operating profit EBITDA|Operating profit EBITDA nextcure.com|Profit before payment of interest, taxes and amortization Leap Therapeutics, Inc. (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Corp (TOVX) - Profit before interest, taxes and amortization|GRTS - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization kinetabio.com KA|NEXI (NexImmune) - Operating profit before deduction of amortization|Turnstone Biologics Corp. (TSBX) - Operating profit EBITDA|Operating profit before deduction of amortization VCNX|HARP (Harpoon Therapeutics Corp) - Company profit before taxes, interest and amortization